在心肌梗塞后的巨极化和心脏功能中MCPIP1的作用
Xingxu Zhang1, Yuan Fang1, Xiaoming Qin1
1Department of Cardiology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, 301 Middle Yanchang Road, Shanghai, 200072, China.
Advanced science (Weinheim, Baden-Wurttemberg, Germany)
|April 26, 2025
概括
单细胞化疗蛋白诱导蛋白1 (MCPIP1) 缺乏症通过破坏巨细胞两极分化和增加铁亡,使心脏病发作恢复恶化. 恢复MCPIP1功能可以改善心脏修复和存活率.
科学领域:
- 免疫学 免疫学 免疫学
- 心血管生物学 心血管生物学
- 细胞生物学 细胞生物学
背景情况:
- 巨细胞对于炎症解消和心脏功能在心肌梗塞 (MI) 后至关重要.
- 大细胞两极分化 (M1/M2表型) 对于心脏中风后的有效心脏修复至关重要.
- MCPIP1 (单细胞化疗蛋白诱导蛋白1) 在调节巨细胞两极分化和心脏恢复方面的作用尚不清楚.
研究的目的:
- 调查MCPIP1在调节心肌梗塞 (MI) 恢复期间巨细胞极化中的功能.
- 探索MCPIP1对心相互作用和铁亡的影响,以MI为背景.
- 评估MCPIP1作为潜在的治疗点,以改善心脏功能.
主要方法:
- 骨髓衍生的巨细胞的组织学染色和RNA测序.
- 共同培养实验和西方斑点验证.
- 在体内研究中,使用骨髓性MCPIP1缺乏的小鼠,包括脊髓切除术,以及用铁死抑制剂 (Fer-1,PFT-α) 治疗.
主要成果:
- 在小鼠中,MCPIP1缺乏导致生存率降低,心脏病发作大小增加,因M1偏振增加和M2转化受损而导致MI后炎症恶化.
- 缺乏MCPIP1促进了巨细胞中的铁亡,而这种过程被抑制剂逆转,增强M2极化和纤维细胞激活.
- 缺乏MCPIP1的小鼠表现出脊髓巨变和循环巨细胞的增加,这表明过度的外母细胞造血;脊髓切除改善了结果.
结论:
- MCPIP1抑制P53/ferroptosis通路,调节巨细胞极化和纤维细胞激活,从而促进心脏的修复后MI.
- 缺乏MCPIP1会通过异常的脏巨细胞输出和恶化的炎症损害心脏修复.
- MCPIP1代表了一个有前途的治疗标,用于调节铁和心沟通,以保护心脏功能.
更多相关视频
相关概念视频
Mitral Valve Prolapse I: Introduction
1.1K
IntroductionThe mitral valve, one of the heart's four valves, regulates blood flow. These valves have flaps that open and close to direct blood properly through the heart and body. During each heartbeat, the flaps open for blood to pass through and seal shut to prevent backflow. Specifically, the mitral valve opens to allow blood flow from the heart's upper left chamber to the lower left chamber. It then closes securely as the lower left chamber contracts to pump blood to the body, preventing...
1.1K
Mitral Stenosis I: Introduction
1.8K
Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
1.8K
Myocarditis I: Introduction
645
Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
645
Myocarditis III: Medical Management
343
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
343
Cardiomyopathy II: Dilated Cardiomyopathy
790
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
790
Cardiomyopathy III: Hypertrophic Cardiomyopathy
805
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
805


